Boston, MA 08/25/2014 (wallstreetpr) – According to reports, BioSpecifics Technologies Corp. (NASDAQ:BSTC) has announced statistically significant, positive double-blind, randomized phase 2A study of CCH. One of the spokespersons of BSTC said that CCH was an ideal treatment of edematous fibro sclerotic panniculopathy or cellulite.
Outcome of the study:
Results of this treatment showed that all the three doses i.e. high, medium and low dose improved the appearance of cellulite. The change in cellulite was measured by the patient-assessed improvements and the trial endpoints of physicians. The entire management of BioSpecifics Technologies Corp. (NASDAQ:BSTC) including President Thomas L. Wegman looked so much encouraged and determined after the positive results. The results were equally encouraging for both patients and physicians because both of them saw a significant improvement in the cellulite appearance after CCH treatment.
In the last few years, the market of cellulite treatment has grown a lot; therefore, these positive results have brought new possibilities and opportunities for CCH treatment. After the successful results, the management of the company is looking forward to taking the study on the next level.
BioSpecifics Technologies Corp. (NASDAQ:BSTC) executed The phase 2a study with the help of its strategic partner Auxilium Pharmaceuticals, Inc. Total 150 women between age group 18-45 were enrolled for this study. All of them received up to three treatment sessions of this drug randomly i.e. 5 high-dose 0.84mg (3 placebo : 5 low (0.06mg): 5 mid (0.48mg)). The average duration between all the treatments was 21 days that gave them enough time to measure the results of the previous studies. The doctors administered up to five injections during every session into cellulite dimples during the complete treatment session across the right posterior thigh or left/right buttock. The researchers came to know that only dimples could be treated on day one, day twenty-two and day forty-three in case the dimple continued to be evident.
